Oct 19, 2011
An update by Barbara D Page on the work done for the first of a 2-year project titled "Using model organisms to identify new therapies and understand the pathogenesis of FSHD."
Sep 6, 2011
The Miller Lab has made exciting progress in the development of a platform for screening genes and compounds with activities that affect FSHD-specific pathogenic processes.
Sep 6, 2011
A major goal of the Seattle FSHD research consortium has been to develop platforms for drug discovery.
Aug 9, 2011
Summary of paper in Molecular Therapy from Joel R. Chamberlain and Davide Gabellini
Oct 29, 2010
An international research consortium shows that FSHD muscle nuclei are poised for expression of the toxic DUX4 protein.
Oct 21, 2010
University of Rochester published interview with Dr. Rabi Tawil.
Sep 20, 2010
An international research collaboration that includes research groups funded by the Friends of FSH Research has made a critical advance in determining the cause of FSHD.
Sep 20, 2010
An international collaboration identifies a region of DNA necessary for FSHD and focuses attention on DUX4 as the cause of muscle deterioration.
Sep 16, 2010
This brought together the various labs which have been collaborating in an effort to push ahead on FSH research through an open exchange of unpublished research.
Jul 25, 2010
Clinical study participants needed.
Jul 15, 2010
Researchers at the Stanford University School of Medicine have developed a technique they believe will help scientists overcome a major hurdle to the use of adult stem cells for treating muscular dystrophy and other muscle-wasting disorders that accompany aging or disease: They've found that growing muscle stem cells on a specially developed synthetic matrix that mimics the elasticity of real muscle allows them to maintain their self-renewing properties.
Jun 26, 2010
Five-year NIH grant to a consortium of FSHD research labs.
Apr 5, 2010
The Muscular Dystrophy Association (MDA), headquartered in Tucson, Ariz., and Friends of FSH Research (FFSHR), based in Kirkland, Wash., today jointly awarded a two-year, $200,000 grant to Joel Chamberlain, research assistant professor of medical genetics at the University of Washington. The grant, equally funded by the two organizations, will enable the laboratory led by Dr. Chamberlain to study RNA interference as an investigative and therapeutic tool for facioscapulohumeral muscular dystrophy.
Mar 9, 2010
The current update of the report on Prevalence or reported number of published cases listed in alphabetical order of disease lists FSHD as occurring in approximately 7 out of 100,000 individuals. This is compared to 5 out of 100,000 individuals for Duchenne and Becker muscular dystrophy, formerly considered the most prevalent form of muscular dystrophy.
Jan 23, 2010
Drs Tapscott and Miller aim to use this grant to finalize the preliminary studies and applications to NIH for funding an international cooperative study on FSHD.
Sep 9, 2009
Dr. Kyba's paper on linking high expression of mDUX to myoblast death.
Aug 1, 2009
FSHD research continues to move forward with the generous help from the Friends of FSH Research. Dr Dan Miller at the University of Washington’s Institute for Stem Cell and Regenerative Medicine, and Dr. Stephen Tapscott at the Fred Hutchinson Cancer Research Center think that one possible cause of muscle weakness in FSHD is a defect in the generation of muscle tissue that may start before birth, and persist as muscles are continually modified and repaired throughout life.
Jun 2, 2009
Facioscapulohumeral muscular dystrophy (FSHD), caused by partial deletion of the D4Z4 macrosatellite repeat on chromosome 4q, has a complex genetic and epigenetic etiology. To develop FSHD, D4Z4 contraction needs to occur on a specific genetic background. Only contractions associated with the 4qA161 haplotype cause FSHD.
Jun 1, 2009
Several genes have been examined as candidates for causing FSHD, including the DUX4 homeobox gene in the D4Z4 repeat, but none have been definitively shown to cause the disease, or has the full extent of transcripts from the D4Z4 region been carefully characterized.
Jun 1, 2009
Research on the cause and treatment of facioscapulohumeral muscular dystrophy (FSHD) might be entering a new, and hopefully better, era. For many years FSHD has been a difficult disease for medical researchers to study. In most genetic diseases, a gene with some known function is mutated and no longer performs its normal biological role. To find a treatment for such a disease, the medical researcher needs to identify therapeutic interventions that will compensate for the mutant gene.
Connect with us on social media